Suzhou Pharmaserve Technology Co., Ltd.

What is Octreotide Acetate?

Octreotide acetate is a longer acting synthetic octapeptide analog of naturally occurring somatostatin. Octreotide acetate inhibits the secretion of gastro-entero-pancreatic peptide hormones and the release of growth hormone. Octreotide also reduces gastrointestinal motility and inhibits contraction of the gall bladder.

First approved for use in the United States in 1988, this longer-acting synthetic peptide is primarily used for the reduction of growth hormone and insulin-like growth factor 1 primarily used in adults with acromegaly and pituitary giantism. was developed by the pharmaceutical company Sandoz.

The chemical structure of octreotide acetate is designed to mimic the structure and actions of somatostatin, a naturally occurring peptide hormone. By modifying somatostatin in this way, octreotide acetate gains a longer duration of action and increased stability in the body, making it suitable for therapeutic use in various medical conditions.

The specific placement of amino acids and the presence of disulfide bonds in its structure are key factors contributing to its pharmacological properties. The “acetate” part of octreotide acetate refers to the presence of an acetate group, typically attached to one of the amino acid residues, usually the N-terminal amino group of the peptide.

What is octreotide acetate used for?Octreotide mechanism of action (MOA) The octreotide acetate MOA is primarily related to its ability to mimic the actions of somatostatin. It works by binding to specific somatostatin receptors (SST receptors) located throughout the body. These receptors are particularly abundant in the gastrointestinal tract, pancreas, and pituitary gland. When octreotide acetate binds to these receptors, it exerts inhibitory effects on hormone secretion, including the following:

Octreotide acetate Pharmaserve slows down gastrointestinal motility. By doing so, it can reduce the rate at which food moves through the digestive tract. This effect is beneficial in conditions associated with diarrhea, such as carcinoid syndrome and certain types of secretory diarrhea. It also inhibits the contraction of the gallbladder. This effect can be relevant in the management of conditions where gallbladder contractions need to be reduced, such as in cases of gallstone-related pain.

Octreotide Pharmaserve is primarily used for growth-hormone lowering therapy in:

Acromegaly: A rare hormonal disorder characterized by excessive production of growth hormone (GH) and physiological transformation, such as enlargement of hands, feet and facial feature, in patients. 95% of all acromegaly cases are caused by an adenoma of the pituitary gland. GH-lowering therapy has an important role in the management of acromegaly, either as a first-line treatment, as an alternative to surgery, or as a second-line treatment, with primary outcomes including tumor shrinkage and biochemical control leading to a normalization of mortality risk with many symptoms improving.

Additionally, octreotide has been used for variety of indications, including:

Who manufactures octreotide acetate?

Pharmaserve is a leading manufacturer of generic active pharmaceutical ingredients (APIs). Pharmaserve began the first and had its first validation batch produced by 2014, with a very high purity far exceeding regulatory thresholds. We manufacture Octreotide acetate production under strict quality control and regulatory guidelines to ensure the purity, stability, and safety of the final pharmaceutical product.